Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 5 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Trial Profile

Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 5 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs BI 690517 (Primary) ; Eplerenone
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 04 Oct 2017 Planned initiation date changed from 20 Sep 2017 to 5 Oct 2017.
    • 18 Sep 2017 Planned initiation date changed from 8 Sep 2017 to 20 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top